BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sur D, Havasi A, Cainap C, Samasca G, Burz C, Balacescu O, Lupan I, Deleanu D, AlexandruIrimie. Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. J Clin Med 2020;9:E182. [PMID: 31936611 DOI: 10.3390/jcm9010182] [Cited by in Crossref: 13] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Keshavarz A, Salehi A, Khosravi S, Shariati Y, Nasrabadi N, Kahrizi MS, Maghsoodi S, Mardi A, Azizi R, Jamali S, Fotovat F. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies. Stem Cell Res Ther 2022;13. [DOI: 10.1186/s13287-022-03163-w] [Reference Citation Analysis]
2 Nenna A, Carpenito M, Chello C, Nappi P, Annibali O, Vincenzi B, Grigioni F, Chello M, Nappi F. Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment. Int J Mol Sci 2022;23:8242. [PMID: 35897819 DOI: 10.3390/ijms23158242] [Reference Citation Analysis]
3 Okamura K, Nagayama S, Tate T, Chan HT, Kiyotani K, Nakamura Y. Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03444-1] [Reference Citation Analysis]
4 Hussain A. Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy. Beni-Suef Univ J Basic Appl Sci 2022;11. [DOI: 10.1186/s43088-022-00238-8] [Reference Citation Analysis]
5 Qian S, Villarejo-campos P, Guijo I, Hernández-villafranca S, García-olmo D, González-soares S, Guadalajara H, Jiménez-galanes S, Qian C. Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects. Front Immunol 2022;13:841425. [DOI: 10.3389/fimmu.2022.841425] [Reference Citation Analysis]
6 Hu LF, Lan HR, Huang D, Li XM, Jin KT. Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand? Front Oncol 2021;11:769305. [PMID: 34888246 DOI: 10.3389/fonc.2021.769305] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Chandra R, Karalis JD, Liu C, Murimwa GZ, Voth Park J, Heid CA, Reznik SI, Huang E, Minna JD, Brekken RA. The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis. Cancers (Basel) 2021;13:6206. [PMID: 34944826 DOI: 10.3390/cancers13246206] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
8 Dang Q, Liu Z, Hu S, Chen Z, Meng L, Hu J, Wang G, Yuan W, Han X, Li L, Sun Z. Derivation and Clinical Validation of a Redox-Driven Prognostic Signature for Colorectal Cancer. Front Oncol 2021;11:743703. [PMID: 34778061 DOI: 10.3389/fonc.2021.743703] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Wang D, Zhang H, Xiang T, Wang G. Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients. Front Immunol 2021;12:762341. [PMID: 34721435 DOI: 10.3389/fimmu.2021.762341] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Aparicio C, Belver M, Enríquez L, Espeso F, Núñez L, Sánchez A, de la Fuente MÁ, González-Vallinas M. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells. Int J Mol Sci 2021;22:11781. [PMID: 34769211 DOI: 10.3390/ijms222111781] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
11 Qian S, Villarejo-Campos P, García-Olmo D. The Role of CAR-T Cells in Peritoneal Carcinomatosis from Gastric Cancer: Rationale, Experimental Work, and Clinical Applications. J Clin Med 2021;10:5050. [PMID: 34768570 DOI: 10.3390/jcm10215050] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Adhikarla V, Awuah D, Brummer AB, Caserta E, Krishnan A, Pichiorri F, Minnix M, Shively JE, Wong JYC, Wang X, Rockne RC. A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy. Cancers (Basel) 2021;13:5171. [PMID: 34680320 DOI: 10.3390/cancers13205171] [Reference Citation Analysis]
13 Zaiachuk M, Pryimak N, Kovalchuk O, Kovalchuk I. Cannabinoids, Medical Cannabis, and Colorectal Cancer Immunotherapy. Front Med (Lausanne) 2021;8:713153. [PMID: 34631734 DOI: 10.3389/fmed.2021.713153] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
14 Pozzi S, Scomparin A, Israeli Dangoor S, Rodriguez Ajamil D, Ofek P, Neufeld L, Krivitsky A, Vaskovich-Koubi D, Kleiner R, Dey P, Koshrovski-Michael S, Reisman N, Satchi-Fainaro R. Meet me halfway: Are in vitro 3D cancer models on the way to replace in vivo models for nanomedicine development? Adv Drug Deliv Rev 2021;175:113760. [PMID: 33838208 DOI: 10.1016/j.addr.2021.04.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
15 Shahnazari M, Samadi P, Pourjafar M, Jalali A. Cell-based immunotherapy approaches for colorectal cancer: main achievements and challenges. Future Oncol 2021;17:3253-70. [PMID: 34156258 DOI: 10.2217/fon-2020-1218] [Reference Citation Analysis]
16 Zeng X, Ward SE, Zhou J, Cheng ASL. Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives. Cancers (Basel) 2021;13:2418. [PMID: 34067719 DOI: 10.3390/cancers13102418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Michel M, Kaps L, Maderer A, Galle PR, Moehler M. The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. Cancers (Basel) 2021;13:2296. [PMID: 34064974 DOI: 10.3390/cancers13102296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
18 Dana H, Chalbatani GM, Jalali SA, Mirzaei HR, Grupp SA, Suarez ER, Rapôso C, Webster TJ. CAR-T cells: Early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B 2021;11:1129-47. [PMID: 34094824 DOI: 10.1016/j.apsb.2020.10.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
19 Cha SE, Kujawski M, J Yazaki P, Brown C, Shively JE. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine. Oncoimmunology 2021;10:1899469. [PMID: 33796409 DOI: 10.1080/2162402X.2021.1899469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zalewski A, Snook AE, Waldman SA. Stem cells as therapeutic targets in colorectal cancer. Per Med 2021;18:171-83. [PMID: 33565332 DOI: 10.2217/pme-2020-0099] [Reference Citation Analysis]
21 Galli F, Varani M, Lauri C, Silveri GG, Onofrio L, Signore A. Immune cell labelling and tracking: implications for adoptive cell transfer therapies. EJNMMI Radiopharm Chem 2021;6:7. [PMID: 33537909 DOI: 10.1186/s41181-020-00116-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Lisby AN, Flickinger JC Jr, Bashir B, Weindorfer M, Shelukar S, Crutcher M, Snook AE, Waldman SA. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Rev Precis Med Drug Dev 2021;6:117-29. [PMID: 34027103 DOI: 10.1080/23808993.2021.1876518] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Yu X, Zhu L, Liu J, Xie M, Chen J, Li J. Emerging Role of Immunotherapy for Colorectal Cancer with Liver Metastasis. Onco Targets Ther 2020;13:11645-58. [PMID: 33223838 DOI: 10.2147/OTT.S271955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
24 Stewart JH 4th, Blazer DG 3rd, Calderon MJG, Carter TM, Eckhoff A, Al Efishat MA, Fernando DG, Foster JM, Hayes-Jordan A, Johnston FM, Lautz TB, Levine EA, Maduekwe UN, Mangieri CW, Moaven O, Mogal H, Shen P, Votanopoulos KI. The Evolving Management of Peritoneal Surface Malignancies. Curr Probl Surg 2021;58:100860. [PMID: 33832580 DOI: 10.1016/j.cpsurg.2020.100860] [Reference Citation Analysis]
25 Ciner AT, Jones K, Muschel RJ, Brodt P. The unique immune microenvironment of liver metastases: Challenges and opportunities. Semin Cancer Biol 2021;71:143-56. [PMID: 32526354 DOI: 10.1016/j.semcancer.2020.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]